Research ExplorerPublicationsCurative therapy of a hepatitis C infection due to an infect...

Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation

Standard

Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation. / Jawad, Khalil; Feder, Stefan; Barten, Markus; Garbade, Jens.

In: EUR J CARDIO-THORAC, Vol. 54, No. 2, 01.08.2018, p. 400-401.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Jawad, K, Feder, S, Barten, M & Garbade, J 2018, 'Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation', EUR J CARDIO-THORAC, vol. 54, no. 2, pp. 400-401. https://doi.org/10.1093/ejcts/ezy051

APA

Jawad, K., Feder, S., Barten, M., & Garbade, J. (2018). Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation. EUR J CARDIO-THORAC, 54(2), 400-401. https://doi.org/10.1093/ejcts/ezy051

Vancouver

Jawad K, Feder S, Barten M, Garbade J. Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation. EUR J CARDIO-THORAC. 2018 Aug 1;54(2):400-401. https://doi.org/10.1093/ejcts/ezy051

Bibtex

@article{87fa62c6bce94ed591b1fa5dd3721943,
title = "Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation",
abstract = "Heart transplantation is the gold standard therapy for patients diagnosed with end-stage heart failure. Despite the shortage of appropriate donor organs, the transplantation of hepatitis C-infected hearts is disputed. Previous research has shown that long-term results are controversial, and the risk of severe clinical infection should not be underestimated.",
keywords = "Adult, Antiviral Agents/therapeutic use, Echocardiography, Heart Failure/surgery, Heart Transplantation/adverse effects, Hepatitis C/drug therapy, Humans, Male, Tissue Donors, Transplants/virology, Viral Load",
author = "Khalil Jawad and Stefan Feder and Markus Barten and Jens Garbade",
note = "Editorial Material",
year = "2018",
month = aug,
day = "1",
doi = "10.1093/ejcts/ezy051",
language = "English",
volume = "54",
pages = "400--401",
journal = "EUR J CARDIO-THORAC",
issn = "1010-7940",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Curative therapy of a hepatitis C infection due to an infected heart donor: 5-year outcomes after heart transplantation

AU - Jawad, Khalil

AU - Feder, Stefan

AU - Barten, Markus

AU - Garbade, Jens

N1 - Editorial Material

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Heart transplantation is the gold standard therapy for patients diagnosed with end-stage heart failure. Despite the shortage of appropriate donor organs, the transplantation of hepatitis C-infected hearts is disputed. Previous research has shown that long-term results are controversial, and the risk of severe clinical infection should not be underestimated.

AB - Heart transplantation is the gold standard therapy for patients diagnosed with end-stage heart failure. Despite the shortage of appropriate donor organs, the transplantation of hepatitis C-infected hearts is disputed. Previous research has shown that long-term results are controversial, and the risk of severe clinical infection should not be underestimated.

KW - Adult

KW - Antiviral Agents/therapeutic use

KW - Echocardiography

KW - Heart Failure/surgery

KW - Heart Transplantation/adverse effects

KW - Hepatitis C/drug therapy

KW - Humans

KW - Male

KW - Tissue Donors

KW - Transplants/virology

KW - Viral Load

U2 - 10.1093/ejcts/ezy051

DO - 10.1093/ejcts/ezy051

M3 - Other (editorial matter etc.)

C2 - 29514173

VL - 54

SP - 400

EP - 401

JO - EUR J CARDIO-THORAC

JF - EUR J CARDIO-THORAC

SN - 1010-7940

IS - 2

ER -